EPIREAD Trademark

Trademark Overview


On Friday, February 2, 2024, a trademark application was filed for EPIREAD with the United States Patent and Trademark Office. The USPTO has given the EPIREAD trademark a serial number of 98388189. The federal status of this trademark filing is REVIVED - AWAITING FURTHER ACTION as of Tuesday, January 6, 2026. This trademark is owned by Moonwalk Biosciences. The EPIREAD trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases, age-related diseases in the nature of neurodegeneration, arthritis, cardiovascular disease, type 2 diabetes, cancer, and osteoporosis, and pediatric diseases in the nature of anemia, asthma, gastrointestinal disorders, skin conditions, neurological disorders, blood disorders, endocrine disorders, developmental or growth disorders, immunological disorders, obesity, and type 1 diabetes; Veterinary pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hem...
epiread

General Information


Serial Number98388189
Word MarkEPIREAD
Filing DateFriday, February 2, 2024
Status616 - REVIVED - AWAITING FURTHER ACTION
Status DateTuesday, January 6, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 7, 2025

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, psychiatric, pulmonary, renal, reproductive, respiratory, and skeletal diseases, age-related diseases in the nature of neurodegeneration, arthritis, cardiovascular disease, type 2 diabetes, cancer, and osteoporosis, and pediatric diseases in the nature of anemia, asthma, gastrointestinal disorders, skin conditions, neurological disorders, blood disorders, endocrine disorders, developmental or growth disorders, immunological disorders, obesity, and type 1 diabetes; Veterinary pharmaceutical preparations and substances for the treatment of autoimmune, cardiometabolic, cardiovascular, dermatological, endocrine, epigenetic, gastrointestinal, genetic, hematological, hemoglobinopathy, immunological, infectious, liver, metabolic, muscular dystrophy, neurodegenerative, neuropsychiatric, oncological, ophthalmological, pulmonary, renal, reproductive, respiratory, and skeletal diseases, and age-related diseases in the nature of arthritis, thyroid imbalance, heart disease, kidney disease, cancer, endocrine disorders, liver disease, obesity, skin, respiratory, gastrointestinal and dental disease

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, February 29, 2024
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameMoonwalk Biosciences
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Party NameMoonwalk Biosciences
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSouth San Francisco, CA 94080

Trademark Events


Event DateEvent Description
Tuesday, February 6, 2024NEW APPLICATION ENTERED
Thursday, February 29, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, May 22, 2024ASSIGNED TO EXAMINER
Thursday, May 23, 2024NON-FINAL ACTION WRITTEN
Thursday, May 23, 2024NON-FINAL ACTION E-MAILED
Thursday, May 23, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, August 19, 2024TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, August 19, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Monday, August 19, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, August 27, 2024FINAL REFUSAL WRITTEN
Tuesday, August 27, 2024FINAL REFUSAL E-MAILED
Tuesday, August 27, 2024NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, October 30, 2024TEAS REQUEST FOR RECONSIDERATION RECEIVED
Wednesday, October 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, December 12, 2024EXAMINERS AMENDMENT -WRITTEN
Thursday, December 12, 2024EXAMINERS AMENDMENT E-MAILED
Thursday, December 12, 2024NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Thursday, December 12, 2024EXAMINER'S AMENDMENT ENTERED
Thursday, December 12, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 1, 2025NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 7, 2025PUBLISHED FOR OPPOSITION
Tuesday, January 7, 2025OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 4, 2025NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Friday, July 11, 2025TEAS REQUEST TO DIVIDE RECEIVED
Monday, January 5, 2026CASE ASSIGNED TO INTENT TO USE PARALEGAL
Friday, July 11, 2025DIVISIONAL REQUEST RECEIVED
Monday, January 5, 2026DIVISIONAL PROCESSING COMPLETE
Monday, January 5, 2026CORRECTED NOA E-MAILED
Monday, January 5, 2026ABANDONMENT - NO USE STATEMENT FILED
Tuesday, January 6, 2026ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Tuesday, January 6, 2026TEAS PETITION TO REVIVE RECEIVED
Tuesday, January 6, 2026PETITION TO REVIVE-GRANTED
Tuesday, January 6, 2026NOTICE OF REVIVAL - E-MAILED